Andrew Guggenhime Sells 10,000 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,979,745.60. This represents a 8.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $53.00, for a total transaction of $530,000.00.

Vaxcyte Trading Up 6.5%

Shares of PCVX stock opened at $60.67 on Wednesday. The stock has a market cap of $8.76 billion, a P/E ratio of -8.82 and a beta of 1.22. The stock has a 50 day simple moving average of $52.16 and a 200 day simple moving average of $53.69. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the company posted ($1.04) earnings per share. Analysts forecast that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on PCVX shares. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and an average price target of $86.00.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds have recently made changes to their positions in PCVX. Smartleaf Asset Management LLC increased its position in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the last quarter. Allworth Financial LP raised its position in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after acquiring an additional 1,350 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.